Dr. Reddys Laboratories Ltd.
BSE: 500124 | NSE: DRREDDY
Mid Cap | Pharmaceuticals & Drugs
1243.00
8.40 (0.68%) Dr.Reddy's Laboratories informs about press release
Date: 19-12-2022Dr.Reddy's Laboratories has informed that it enclosed Press Release titled 'Dr. Reddy's successfully completes Phase 1 study of DRL_TC, a proposed biosimilar of tocilizumab’.
The above information is a part of company’s filings submitted to BSE.